Ligand Pharmaceuticals Inc
NASDAQ:LGND

Watchlist Manager
Ligand Pharmaceuticals Inc Logo
Ligand Pharmaceuticals Inc
NASDAQ:LGND
Watchlist
Price: 116.65 USD 1.75% Market Closed
Market Cap: 2.2B USD
Have any thoughts about
Ligand Pharmaceuticals Inc?
Write Note

Ligand Pharmaceuticals Inc
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Ligand Pharmaceuticals Inc
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Ligand Pharmaceuticals Inc
NASDAQ:LGND
Total Current Liabilities
$24.8m
CAGR 3-Years
-12%
CAGR 5-Years
-7%
CAGR 10-Years
3%
Abbvie Inc
NYSE:ABBV
Total Current Liabilities
$43.1B
CAGR 3-Years
15%
CAGR 5-Years
20%
CAGR 10-Years
21%
Gilead Sciences Inc
NASDAQ:GILD
Total Current Liabilities
$11.7B
CAGR 3-Years
5%
CAGR 5-Years
4%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Total Current Liabilities
$20.3B
CAGR 3-Years
11%
CAGR 5-Years
14%
CAGR 10-Years
9%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Current Liabilities
$4B
CAGR 3-Years
28%
CAGR 5-Years
23%
CAGR 10-Years
27%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Current Liabilities
$3.7B
CAGR 3-Years
0%
CAGR 5-Years
16%
CAGR 10-Years
24%
No Stocks Found

Ligand Pharmaceuticals Inc
Glance View

Market Cap
2.2B USD
Industry
Biotechnology

In the bustling world of pharmaceuticals, Ligand Pharmaceuticals Inc. carves a distinct niche for itself as a company that thrives not on direct consumer market engagements but through the engines of innovation and strategic collaboration. Founded in 1987, Ligand has developed a business model centered around drug discovery and development technologies, as well as licensing these advancements to major pharmaceutical partners. Rather than manufacturing products directly for the consumer, Ligand's prowess lies in its proprietary technology platforms, such as Captisol, and its ability to monetize its intellectual properties through alliances. This allows Ligand to fuel a diverse pipeline of partnered products without bearing the risks and costs typically associated with late-stage drug development and commercialization. The company's financial ecosystem is further enriched by royalties, milestone payments, and licensing fees derived from over a hundred medications it has helped bring to market through its partnerships. By providing the technological backbone for novel therapies used in treating cancer, osteoporosis, fungal infections, and more, Ligand benefits financially when its partners succeed in commercializing drugs. This symbiotic model not only maximizes research and development efficiencies for Ligand but also positions the company as a crucial player in the value chain of the pharmaceutical industry. Their approach effectively balances innovation with financial prudence, enabling Ligand to focus on expanding its platform capabilities while diversifying its revenue streams.

LGND Intrinsic Value
82.48 USD
Overvaluation 29%
Intrinsic Value
Price

See Also

What is Ligand Pharmaceuticals Inc's Total Current Liabilities?
Total Current Liabilities
24.8m USD

Based on the financial report for Sep 30, 2024, Ligand Pharmaceuticals Inc's Total Current Liabilities amounts to 24.8m USD.

What is Ligand Pharmaceuticals Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
3%

Over the last year, the Total Current Liabilities growth was 58%. The average annual Total Current Liabilities growth rates for Ligand Pharmaceuticals Inc have been -12% over the past three years , -7% over the past five years , and 3% over the past ten years .

Back to Top